Mechanism of EGR2 in Allergic Rhinitis

Study Overview
=================
Brief Summary
-----------------
EGR2 may be a target for the treatment of nasal polyps.

Detailed Description
-----------------
There is much debate about the etiology of nasal polyps, so the pathogenesis of nasal polyps still needs to be clarified. Surgery for noninflammatory nasal polyps may be better control, but surgery is not effective for recurrent sinusitis and nasal polyps. Therefore, more research is needed to determine the best targeted therapy for nasal polyps. We found that EGR2 expression was upregulated in CRSwNP patients with allergic rhinitis.In addition, the expression of EGR2 in CRSwNP mucosa was significantly higher than that in the control group, and the expression of EGR2 in CRSwNP with allergic rhinitis was higher than that in CRSwNP without allergic rhinitis. EGR2 may be involved in the pathogenesis of nasal polyps, and may also be related to the severity and recurrence of nasal polyps. EGR2 may be a target for the treatment of nasal polyps.

Official Title
-----------------
The Regulatory Mechanism of EGR2 Mediated by miR-150-5p on Allergic Rhinitis

Conditions
-----------------
Rhinitis, Allergic

Intervention / Treatment
-----------------
* Genetic: EGR2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients were stopped by systemic or topical corticosteroid treatment at least one month before the study. Exclusion Criteria: Patients had NPs accompanied by choanal polyps, fungal nasal sinusitis, cystic fibrosis, acute upper airway upper infection or other systemic diseases.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 76 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: immunohistochemistry<br>Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by immunohistochemistry | Genetic: EGR2<br>* We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.<br>|
| Experimental: WestBlot<br>Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by Western Blot. | Genetic: EGR2<br>* We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| expression of EGR2 | expression of EGR2 were analyzed by immunohistochemistry and Western Blot | one months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EGR2, atopic NPs, nasal polyps, chronic rhinosinusitis, non-atopic NPs